Coloplast reported marginally softer than expected Q2 22 numbers, as sales were up 7% with broad-based growth across products. Adjusted EBIT margin was down 200bp, hurt by relatively faster operating expense growth.
However, management cut FY22 expectations: organic growth of 6-7% (vs 7% earlier), and reported EBIT margin of 28-29% (vs 30% earlier), sending the stock 11% lower since the announcement.
We will trim our estimates by 1-2% to factor in the soft FY22 outlook.
06 May 2022
Q1 22: guidance cut spooks investors
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 22: guidance cut spooks investors
- Published:
06 May 2022 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast reported marginally softer than expected Q2 22 numbers, as sales were up 7% with broad-based growth across products. Adjusted EBIT margin was down 200bp, hurt by relatively faster operating expense growth.
However, management cut FY22 expectations: organic growth of 6-7% (vs 7% earlier), and reported EBIT margin of 28-29% (vs 30% earlier), sending the stock 11% lower since the announcement.
We will trim our estimates by 1-2% to factor in the soft FY22 outlook.